By considering some encouraging pre-clinical results, several clinical trials have started testing bi-specific agents directed against MM-associated antigens, such as BCMA, CD38, CD19, GPRC5D, and FcRH5 [131]. This evidence concerns the gene CD38 and Miyoshi myopathy.